

## VETOQUINOL FINALIZES THE ACQUISITION OF PROFENDER® AND DRONTAL® PRODUCT FAMILIES

September 1<sup>st</sup>, 2020 (Lure, France) – Vetoquinol confirms the completion of the acquisition of Profender® and Drontal® product families for the European Economic Area and the UK. This acquisition is effective from August 1<sup>st</sup>, 2020.

Vetoquinol has acquired the Profender® and Drontal® product families, the intellectual property, registrations and other rights previously owned by Bayer AG's animal health business. The Profender® and Drontal® families of products are spot-on and tablet de-wormer products for cats and dogs.

Vetoquinol's acquisition of Profender® and Drontal® is related to Elanco's acquisition of Bayer AG's animal health business, which was finalized on August 1<sup>st</sup> 2020.

Matthieu Frechin, CEO of Vetoquinol, said *"We are extremely pleased to share the completion of the acquisition of the Profender® and Drontal® product lines. These two strong brands fit perfectly at the core of Vetoquinol strategy. From now on, they will significantly increase the size of our business and our visibility in the parasiticide segment, one of our strategic therapeutic areas. Also, effective immediately, these products and brands strengthen our portfolio of Essentials, the engine of our growth. I am proud of the Vetoquinol teams who made this deal happen despite the challenging circumstances brought by the global COVID outbreak."*

**Next update:** Q3 Sales results October 15<sup>th</sup> 2020 after market close

### **About Vetoquinol**

Vetoquinol is a leading global animal health company that supplies drugs and non-medicinal products for the livestock (cattle and pigs) and pet (dogs and cats) markets.

As an independent pure player, Vetoquinol designs, develops and sells veterinary drugs and non-medicinal products in Europe, the Americas and the Asia Pacific region.

Since its foundation in 1933, Vetoquinol has pursued a strategy combining innovation with geographical diversification. The Group's hybrid growth is driven by the reinforcement of its product portfolio coupled with acquisitions in high potential growth markets. At June 30<sup>th</sup> 2020, Vetoquinol employs 2,401 people.

Vetoquinol has been listed on Euronext Paris since 2006 (symbol: VETO).

**For further information, go to:** [www.vetoquinol.com](http://www.vetoquinol.com).

For more information, contact:

#### **VETOQUINOL**

Investor Relations

Fanny Toillon

Tel.: +33 (0)3 84 62 59 88

[relations.investisseurs@vetoquinol.com](mailto:relations.investisseurs@vetoquinol.com)

#### **KEIMA COMMUNICATION**

Investor and Media Relations

Emmanuel Dovergne

Tel.: +33 (0)1 56 43 44 63

[emmanuel.dovergne@keima.fr](mailto:emmanuel.dovergne@keima.fr)